Electrophysiological properties of cardiomyocytes isolated from CYP2J2 transgenic mice

被引:27
作者
Ke, Qingen
Xiao, Yong-Fu
Bradbury, J. Alyce
Graves, Joan P.
DeGraff, Laura M.
Seubert, John M.
Zeldin, Darryl C.
机构
[1] NIEHS, NIH, Div Intramural Res, Res Triangle Pk, NC 27709 USA
[2] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Cardiovasc Div, Boston, MA 02115 USA
关键词
D O I
10.1124/mol.107.035881
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
CYP2J2 is abundant in cardiac tissue and active in the biosynthesis of eicosanoids such as epoxyeicosatrienoic acids (EETs). To determine the effects of CYP2J2 and its eicosanoid products in the heart, we characterized the electrophysiology of single cardiomyocytes isolated from adult transgenic (Tr) mice with cardiac-specific overexpression of CYP2J2. CYP2J2 Tr cardiomyocytes had a shortened action potential. At 90% repolarization, the action potential duration (APD) was 30.6+/-3.0 ms (n+/-22) in wild-type (Wt) cells and 20.2+/-2.3 ms (n+/-19) in CYP2J2 Tr cells (p+/-0.005). This shortening was probably due to enhanced maximal peak transient outward K+ currents ( I to, peak), which were 38.6+/-2.8 and 54.4+/-4.9 pA/pF in Wt and CYP2J2 Tr cells, respectively (p+/-0.05). In contrast, the late portion of the transient outward K+ current (I-to,I-280ms), the slowly inactivating outward K+ current (I-K,I-slow), and the voltage-gated Na+ current (I-Na) were not significantly altered in CYP2J2 Tr cells. N-Methylsulphonyl-6-(2-proparglyloxy-phenyl) hexanamide (MS-PPOH), a specific inhibitor of EET biosynthesis, significantly reduced I-to,I-peak and increased APD in CYP2J2 Tr cardiomyocytes but not in Wt cells. Intracellular dialysis with a monoclonal antibody against CYP2J2 also significantly reduced I-to,I-peak and increased APD in CYP2J2 Tr cardiomyocytes. Addition of 11,12-EET or 8-bromo- cAMP significantly reversed the MS-PPOH- or monoclonal antibody-induced changes in I-to,I-peak and APD in CYP2J2 Tr cells. Together, our data demonstrate that shortening of the action potential in CYP2J2 Tr cardiomyocytes is associated with enhanced I-to,I-peak via an EET-dependent, cAMP-mediated mechanism.
引用
收藏
页码:1063 / 1073
页数:11
相关论文
共 40 条
[1]   CYTOCHROME-P450 MAY REGULATE PLASMA-MEMBRANE CA2+ PERMEABILITY ACCORDING TO THE FILLING STATE OF THE INTRACELLULAR CA2+ STORES [J].
ALVAREZ, J ;
MONTERO, M ;
GARCIASANCHO, J .
FASEB JOURNAL, 1992, 6 (02) :786-792
[2]   Kv4.2 phosphorylation by cyclic AMP-dependent protein kinase [J].
Anderson, AE ;
Adams, JP ;
Qian, Y ;
Cook, RG ;
Pfaffinger, PJ ;
Sweatt, JD .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (08) :5337-5346
[3]  
Brand-Schieber E, 2000, J PHYSIOL PHARMACOL, V51, P655
[4]   Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors [J].
Campbell, WB ;
Gebremedhin, D ;
Pratt, PF ;
Harder, DR .
CIRCULATION RESEARCH, 1996, 78 (03) :415-423
[5]   Adenosine2A receptor vasodilation of rat preglomerular microvessels is mediated by EETs that activate the cAMP/PKA pathway [J].
Carroll, Mairead A. ;
Doumad, Anabel B. ;
Li, Jing ;
Cheng, Monica K. ;
Falck, J. R. ;
McGiff, John C. .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2006, 291 (01) :F155-F161
[6]   Inhibition of cardiac L-type calcium channels by epoxyeicosatrienoic acids [J].
Chen, JY ;
Capdevila, JH ;
Zeldin, DC ;
Rosenberg, RL .
MOLECULAR PHARMACOLOGY, 1999, 55 (02) :288-295
[7]  
Gelboin H V, 1998, Methods Mol Biol, V107, P227
[8]   Reduction of ischemia and reperfusion-induced myocardial damage by cytochrome P450 inhibitors [J].
Granville, DJ ;
Tashakkor, B ;
Takeuchi, C ;
Gustafsson, AB ;
Huang, CQ ;
Sayen, MR ;
Wentworth, P ;
Yeager, M ;
Gottlieb, RA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (05) :1321-1326
[9]   Cytochrome P450 ω-hydroxylase inhibition reduces infarct size during reperfusion via the sarcolemmal KATP channel [J].
Gross, ER ;
Nithipatikom, K ;
Hsu, AK ;
Peart, JN ;
Falck, JR ;
Campell, WB ;
Gross, GJ .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2004, 37 (06) :1245-1249
[10]   Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases [J].
Imig, JD .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2005, 289 (03) :F496-F503